# A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors

> **NCT07253116** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nanjing Jingao biomidical technology Co. Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** WJ22096

## Key facts

- **NCT ID:** NCT07253116
- **Lead sponsor:** Nanjing Jingao biomidical technology Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07253116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07253116, "A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07253116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*